Key findings
- 0.73 vs 0.71AUC for renal decline in type 2 diabetes: serum sTNFR1 alone versus the combined UACR–eGFR model
- 67% and 92%sensitivity and specificity of the urinary KIM-1-to-creatinine ratio for moderately increased albuminuria in 80 patients with T2DM and eGFR above 60
- 0.835 to 0.896rise in the C-statistic for renal progression prediction after adding an optimised multi-marker panel
- 40–70%of diabetic CKD is the non-albuminuric phenotype that UACR screening fails to identify
Abstract
- Purpose
- Diabetic kidney disease is a leading cause of end-stage renal disease, with a rapidly rising burden in India. Microalbuminuria and estimated glomerular filtration rate detect disease only after substantial irreversible nephron loss, and up to 70% of diabetic patients with declining renal function remain normoalbuminuric. This narrative review critically examines evidence published mainly from 2018 onward on newer serum and urinary biomarkers for the early detection of diabetic kidney disease and stratification of its progression risk, with emphasis on applicability within Indian clinical practice.
- Methods
- Literature was searched across PubMed, Scopus, and Web of Science; IndMED and Google Scholar were additionally consulted for Indian studies. Biomarkers were grouped by pathophysiological category: inflammation, tubular damage, glomerular and podocyte injury, oxidative stress, and other emerging indicators. Reported sensitivity, specificity, and area under the receiver operating characteristic curve were extracted wherever available to allow comparison between biomarkers.
- Results
- Soluble tumour necrosis factor receptor 1, kidney injury molecule-1, and neutrophil gelatinase-associated lipocalin emerged as the most reproducibly validated candidates for pre-albuminuric detection. Soluble tumour necrosis factor receptor 1 predicted a decline of more than 30% in renal function with 66% sensitivity and 75% specificity, and its area under the curve was comparable with that of albuminuria combined with estimated glomerular filtration rate (0.73 versus 0.71), independently of these conventional markers. The urinary kidney injury molecule-1-to-creatinine ratio identified moderately increased albuminuria with 67% sensitivity, 92% specificity, and an area under the curve of 0.84, whereas urinary neutrophil gelatinase-associated lipocalin showed 80% sensitivity and 61% specificity. Multi-marker panels raised the C-statistic for progression prediction from 0.835 to 0.896. Circulating microRNAs (pooled sensitivity 76%, specificity 74%) and the podocyte proteins nephrin and podocalyxin showed encouraging preliminary results that await larger-cohort validation.
- Conclusion
- Stepwise incorporation of cystatin C, urinary kidney injury molecule-1, urinary neutrophil gelatinase-associated lipocalin, and serum soluble tumour necrosis factor receptor 1 into Indian clinical biochemistry workflows would meaningfully improve upon albuminuria-based screening alone. Assay standardisation, cost-effectiveness analyses, and population-specific reference intervals remain priorities for Indian laboratories.
Highlights
- sTNFR1 predicts renal decline in type 2 diabetes independently of UACR and eGFR (AUC 0.73 versus 0.71; sensitivity 66%, specificity 75%).
- KIM-1 and NGAL detect tubular injury before microalbuminuria appears.
- Multi-marker panels raise the C-statistic from 0.835 to 0.896.
- Reported sensitivity, specificity, and AUC values are compiled so that candidate biomarkers can be compared.
- 40–70% of diabetic CKD is normoalbuminuric and missed by UACR screening.
- A stepwise approach for adopting these biomarkers in Indian laboratory settings is proposed.
Introduction
Diabetic nephropathy is a major microvascular complication of diabetes, affecting approximately one in three individuals with type 1 or type 2 diabetes.1 It is among the leading causes of end-stage renal disease (ESRD) and chronic kidney disease (CKD) worldwide, and is associated with elevated morbidity and mortality, particularly in type 2 diabetes mellitus (T2DM).2 The condition follows a course from normoalbuminuria through microalbuminuria and macroalbuminuria to ESRD, developing in about 40% of T2DM patients within ten years of diagnosis.3,4 Its pathogenesis is complex, involving inflammatory, genetic, and epigenetic mechanisms,5 together with hyperglycaemia-driven overproduction of reactive oxygen species (ROS).1 An estimated 589 million adults aged 20–79 years were living with diabetes in 2024, and this number is projected to rise to 853 million by 20506; the associated kidney-disease burden is therefore expected to grow further. Despite established screening protocols, the condition remains underdiagnosed,7 and no biomarker reliably forecasts the risk of progression.2 Early detection and timely intervention therefore remain clinical priorities.
Rationale for a Narrative Review
Identification of early, specific biomarkers has become a focus of recent research, as earlier diagnosis may permit timely treatment and retard disease progression.3 Although several reviews have introduced newer serum and urine biomarkers, an updated narrative synthesis is necessary to consolidate evidence, fill knowledge gaps, and provide actionable clinical guidance.2 Reported molecular biomarkers span genes, proteins, metabolites, glycans, and related molecules, and elevated levels have been observed in T2DM individuals across normoalbuminuric, microalbuminuric, and macroalbuminuric categories—making them of potential value for early identification before clinical manifestation.3 A narrative approach also accommodates emerging themes such as recently described biomarkers and therapeutic strategies that may alter disease trajectory,5 which a strictly systematic design would not readily integrate. To keep the review focused on early detection, mechanistic background is limited to what is needed to interpret each marker, and candidates supported mainly by experimental or non-diabetic data are mentioned only briefly. Wherever available, sensitivity, specificity, and area under the receiver operating characteristic curve (AUC) are reported numerically, and the main candidates are compared in Section 10.
This review focuses on laboratory biomarkers that may detect early diabetic nephropathy before microalbuminuria appears or predict its course better than microalbuminuria.3 Microalbuminuria, long considered the first detectable indicator, has considerable limitations—variability, low sensitivity, and an inability to reliably predict a renal outcome specific to diabetic nephropathy1,3—and a substantial proportion of renal impairment reportedly occurs before its appearance.1 Conventional diagnostic approaches such as albuminuria quantification and serum creatinine are frequently inadequate for identifying early damage.2,5 Several recently described urinary and serum biomarkers detect diabetic nephropathy at earlier stages than proteinuria, often before significant urinary albumin appears.2 Urinary proteomics has identified numerous additional markers that classify diabetic nephropathy and predict disease with a mean lead time of 1.5 years ahead of stage A2 albuminuria onset and up to five years earlier in some individuals.7
Biomarkers are organised according to their association with pathogenesis, pathology, and renal-function changes, and are summarised in Table 1.4
Table 1. Summary of candidate biomarkers for early diabetic kidney disease discussed in this review. ↑, increased; 8-OHdG, 8-hydroxy-2′-deoxyguanosine; CD146, cluster of differentiation 146; CE-MS, capillary electrophoresis–mass spectrometry; ELISA, enzyme-linked immunosorbent assay; hs-CRP, high-sensitivity C-reactive protein; IL-6, interleukin 6; KIM-1, kidney injury molecule-1; L-FABP, liver-type fatty acid-binding protein; MCP-1, monocyte chemoattractant protein-1; miRNA, microRNA; NAG, N-acetyl-β-D-glucosaminidase; NGAL, neutrophil gelatinase-associated lipocalin; POC, point of care; qPCR, quantitative polymerase chain reaction; sTNFR, soluble tumour necrosis factor receptor; VEGF-A, vascular endothelial growth factor A
| Biomarker | Domain | Sample | Direction | Assay | Indian data |
|---|---|---|---|---|---|
| Cystatin C | Filtration | Serum | ↑ | Turbidimetry | Yes |
| sTNFR1 | Inflammatory | Serum | ↑ | ELISA | Limited |
| sTNFR2 | Inflammatory | Serum | ↑ | ELISA | Limited |
| KIM-1 | Tubular | Urine/plasma | ↑ | ELISA | Some |
| NGAL | Tubular | Urine/serum | ↑ | ELISA; POC | Yes |
| L-FABP | Tubular | Urine | ↑ | ELISA | Limited |
| NAG | Tubular | Urine | ↑ | Colorimetric | Yes |
| Nephrin | Podocyte | Urine | ↑ | ELISA | Limited |
| Podocalyxin | Podocyte | Urine | ↑ | ELISA | Limited |
| IL-6 | Inflammatory | Serum/urine | ↑ | ELISA | Yes |
| MCP-1 | Chemokine | Urine | ↑ | ELISA | Limited |
| hs-CRP | Acute-phase | Serum | ↑ | Nephelometry | Yes |
| 8-OHdG | Oxidative | Urine | ↑ | ELISA | Limited |
| CD146 | Endothelial | Plasma | ↑ | ELISA | No |
| VEGF-A | Angiogenic | Serum/urine | ↑ | ELISA | Limited |
| miR-21 | miRNA | Plasma/urine | ↑ | qPCR | No |
| CKD273 | Proteomic | Urine | ↑ | CE-MS | No |
Categories include glomerular markers, tubular biomarkers, and markers of oxidative stress and inflammation5; the corresponding anatomical compartments of origin within the nephron are schematically illustrated in Figure 1.
In the concluding sections, a comparative assessment of biomarker performance is presented, followed by a discussion on the gaps that exist in the current evidence, considerations that are specific to the Indian clinical setting, and directions that future research in this area should take.
Literature Search Strategy
For the purpose of this review, a literature search was performed using PubMed, Scopus, and Web of Science as the primary databases. The search terms employed included various combinations of “diabetic kidney disease,” “diabetic nephropathy,” “biomarker,” “early detection,” and names of individual markers. To retrieve studies conducted in India, the databases IndMED and Google Scholar were also searched. All retrieved articles were imported into a reference manager, and after removal of duplicates, two reviewers working independently carried out screening of titles and abstracts, followed by full-text evaluation against eligibility criteria defined in advance.2 Proceedings of international conferences and supplementary publications found through the bibliographies of eligible articles were also evaluated for possible inclusion.3 Position statements and practice recommendations issued by clinical working groups concerned with the detection, monitoring, and slowing of diabetic nephropathy progression were taken into account; these covered diagnostic standards, updated screening protocols, emerging detection methods, and revised therapeutic approaches.7 Evidence published from 2018 onwards was given priority, with particular attention paid to early biomarkers belonging to the domains of oxidative stress, inflammatory cytokines, glomerular filtration membrane damage, and tubulointerstitial injury.4,5 For each biomarker, the study population, target condition, cut-off value, sensitivity, specificity, and AUC were extracted when reported. Mechanistic and experimental studies were retained only where they were needed to explain the biological basis of a marker.
Limitations of Traditional Markers and the Need for New Biomarkers
Urinary Albumin-to-Creatinine Ratio: Variability, Delayed Rise, and Normoalbuminuric Disease
Urinary albumin-to-creatinine ratio (UACR) has historically served as the first-line screening tool for DKD, but it fails to identify the non-albuminuric phenotype, which now accounts for 40–70% of diabetic CKD.8,9 Because normoalbuminuric DKD is not accompanied by proteinuria, it is frequently overlooked under current diagnostic approaches.9 UACR is also highly variable: intraindividual excretion ranges from 4% to 103%, and values are influenced by fever, infection, and hypertension, making single measurements unreliable.9 Single-specimen reliance carries a greater misclassification risk than the stricter criterion of at least two of three sequential specimens falling in the same albuminuria category.8,10 The non-albuminuric phenotype is more common in older patients and in women, with proposed mechanisms including vascular disease progression, age-related renal changes, and pathways partly independent of glycaemic and blood-pressure control.10 These observations support the inclusion of tubular-function markers alongside albuminuria in routine annual screening from the time of diabetes diagnosis.
Estimated Glomerular Filtration Rate: Insensitivity to Early Damage
Routinely used markers—serum creatinine, eGFR, and proteinuria—share a fundamental limitation: none detects early structural changes in the kidney, and eGFR captures only late functional decline rather than the preceding injury.11 Serum creatinine is additionally influenced by muscle mass, since approximately 95% of creatine resides within muscle tissue.12 In older patients, progressive muscle loss lowers creatinine production at a rate parallel to the decline in filtration, masking genuine renal impairment.13 Given the limited efficacy of current therapies for CKD, the development of novel molecular diagnostics capable of identifying patients early in the disease course is therefore essential.11,14
The Concept of Early Diabetic Nephropathy
Microalbuminuria—sustained albumin excretion of 30 to 300 mg/day, below the threshold detectable by dipstick urinalysis—is conventionally considered the earliest detectable abnormality in diabetic nephropathy.15,16 It reflects glomerular injury and has independent prognostic significance for both cardiovascular disease and progressive renal decline.3,15 Among newly diagnosed T2DM patients, up to 30% already have elevated urinary albumin, of which roughly 75% fall in the microalbuminuric range.16 Annual screening is therefore recommended from five years post-diagnosis in type 1 diabetes and from diagnosis onwards in type 2.15 However, microalbuminuria may be absent during the initial phase of renal injury3; by the time it becomes measurable, substantial glomerulopathy has usually already developed, and a proportion of patients subsequently revert to normoalbuminuria.15 Mean serum cystatin C was reported to be higher in patients with diabetic nephropathy (1.87 ± 0.51 mg/L) than in those without (1.025 ± 0.30 mg/L), and higher in microalbuminuric than in normoalbuminuric T2DM patients, supporting it as a candidate marker that may precede both microalbuminuria and serum creatinine in signalling renal compromise.3
Emerging Alternatives to Conventional Markers
Despite its status as an independent risk factor for both CKD progression and cardiovascular events, routine ACR assessment remains underutilised even in high-income settings, and CKD-attributable morbidity and mortality continue to vary substantially by income level and geographic location.17 Creatinine-based eGFR is an improvement over serum creatinine alone but retains meaningful limitations under conditions of hyperfiltration.18 Kidney injury molecule-1 (KIM-1) and neutrophil gelatinase-associated lipocalin (NGAL) signal tubular injury earlier than creatinine, and cystatin C has been reported to detect CKD more sensitively than serum creatinine and UACR (quantitative data are given in Section 9.1)—although cost continues to constrain its use for population-level screening.19
In recent years, urinary proteome profiling has come to be regarded as an approach of considerable promise for arriving at an early diagnosis.19,20 In this context, urinary Mindin—which was found to be raised in T2DM patients and showed a sensitivity of 68%, a specificity of 86.96%, and an area under the curve (AUC) value of 0.87—has been put forward as a marker that specifically reflects podocyte injury and can be detected in the urine at a stage that precedes the appearance of overt proteinuria.20 To minimise the possibility of a wrong diagnosis, it is advisable that any abnormal result be confirmed by a repeat measurement performed after an interval of at least three months.19
Pathophysiological Basis for Biomarker Discovery
Inflammation as a Driver of Diabetic Kidney Injury
Inflammation is now established as a central driver of DKD initiation and progression, acting across both glomerular and tubulointerstitial compartments.21,22 Chronic hyperglycaemia drives renal tubular cells to produce ICAM-1, MCP-1, and osteopontin, recruiting circulating macrophages and monocytes, while simultaneously stimulating secretion of IL-1β, IL-6, and TNF-α.20,22 Advanced glycation end products (AGEs) further upregulate adhesion molecules and chemokines in kidney cells.21 The NLRP3 inflammasome—activated by ROS—sustains a self-reinforcing inflammation–oxidative stress cycle.23 Inhibition of leucocyte recruitment in diabetic animal models conferred protection against albuminuria and structural damage, supporting a causal rather than merely reactive role.24 Among inflammatory markers studied to date, tumour necrosis factor receptors 1 and 2 appear to carry the greatest promise for clinical application in DKD.21
Tubular Injury in Early Diabetic Kidney Disease
Traditional frameworks have emphasised glomerular injury, but accumulating evidence indicates that renal tubules contribute equally to outcomes and that tubular lesions may emerge before glomerular pathology—giving rise to the concept of diabetic tubulopathy as a distinct clinical entity.25,26 Urinary tubular markers are often elevated in diabetic patients before microalbuminuria appears; urinary KIM-1, for example, has been documented above control levels at a stage preceding microalbuminuria.27 Elevated glucose, free glycation adducts, ROS, and oxidised lipids exert direct cytotoxic effects on tubular epithelial cells, and tubulointerstitial pathology can develop independently of glomerular disease in type 1 diabetes.28 In patients with glomerular hyperfiltration, NGAL and KIM-1 excretion correlates positively with GFR, supporting proximal tubular injury as a primary rather than secondary event in early DKD.26,28
Glomerular and Fibrotic Pathways
DKD pathogenesis involves mesangial cell proliferation, mesangial expansion, glomerular basement membrane thickening, podocyte detachment, and tubulointerstitial damage, cumulatively producing diffuse glomerulosclerosis and loss of filtration surface area.29 Transforming growth factor-β (TGF-β) is a central fibrotic mediator: hyperglycaemia-induced matrix accumulation proceeds through TGF-β signalling, and early DKD shows increased glomerular deposition of both mRNA and protein.24,30 Podocyte injury is equally central: podocytes cannot replicate, so their depletion is irreversible and marks a decisive step toward glomerulosclerosis.31,32
Oxidative Stress and Endothelial Dysfunction
Oxidative stress is the predominant pathogenic mechanism in diabetes: excess generation of ROS coupled with failure of antioxidant defences triggers endothelial dysfunction, chiefly by reducing nitric oxide (NO) bioavailability.20,33 Endothelial dysfunction is multifactorial, driven by hyperglycaemia, AGEs, free fatty acids, modified LDL, ageing, and chronic inflammation—collectively establishing a proinflammatory and prothrombotic vascular state.34 These processes provide the rationale for the oxidative stress and endothelial markers discussed in Sections 8 and 9.
Inflammatory Biomarkers
Soluble Tumour Necrosis Factor Receptors 1 and 2
Tumour necrosis factor receptors 1 and 2 (TNFR1, TNFR2) are proteolytically cleaved from transmembrane receptors to yield soluble forms that function as endogenous inhibitors of TNF-α signalling.35 TNFR1 predominantly activates proinflammatory cascades, while TNFR2 mediates antiapoptotic responses.36 The relevance of this axis to DKD is substantial, since hyperglycaemia- and hypertension-driven inflammation is an essential pathogenic event that precedes detectable changes in albuminuria or eGFR.37
Circulating sTNFR1 has emerged as one of the most reproducible biomarkers of DKD. Serum sTNFR1 predicts ESRD risk in T2DM independently of baseline UACR and eGFR.37 In elderly populations, higher TNFR1 independently predicts progression to a worse GFR category and incident CKD, and the highest quartiles of TNFR1 and TNFR2 correlate with elevated creatinine, cystatin C, and urinary protein alongside lower eGFR values.36 Both receptors associate with eGFR deterioration, and sTNFR1 has been reported to correlate with eGFR (R = –0.52) and ACR (R = 0.22); among rapid decliners, individuals in the highest TNFR quartile showed an eGFR decline rate of 1.60% per month.35,36
Against the combined UACR–eGFR model, sTNFR1 showed non-inferior predictive performance for renal risk (AUC 0.73 versus 0.71), with the practical advantage of direct quantification by commercial assay rather than calculation-based estimation.37 Among 17 inflammatory signature proteins evaluated, sTNFR1 demonstrated the greatest predictive capacity for ESRD.38 Concentrations ≥12.48 pg/dL carried an adjusted hazard ratio of 2.65 for eGFR decline greater than 30%; at this cut-off, sTNFR1 predicted such a decline with 66% sensitivity and 75% specificity over a mean follow-up of 5.5 years in 416 patients with T2DM.37 Increasing sTNFR1 levels were also a more dominant predictor of ESRD than either albuminuria or baseline renal function.37 Because up to 50% of functioning nephrons may already be lost by the time moderately elevated albuminuria or an eGFR below 60 mL/min/1.73 m2 becomes detectable, a marker that is active earlier in the disease course carries considerable clinical value.37
Interleukins 6, 1β, and 18
Serum IL-6 is directly linked to early glomerular structural abnormalities and is substantially elevated in T2DM patients with diabetic nephropathy relative to those without renal involvement; both serum and urinary IL-6 concentrations are further increased in proteinuric patients compared with normoalbuminuric or microalbuminuric controls.39 IL-1β, produced by monocytes, macrophages, and dendritic cells, drives systemic inflammation through hepatic CRP induction, endothelial activation, and leucocyte mobilisation.40 IL-18, secreted on inflammasome activation, induces interferon-γ production from T and NK cells and is markedly upregulated in the kidney after injury.40 Serum and urinary IL-18 concentrations are significantly higher in proteinuric than non-proteinuric T2DM patients, and elevation of both IL-6 and IL-18 at mRNA and protein levels provides a basis for further investigation as clinical predictors of diabetic nephropathy.39 However, paired sensitivity and specificity estimates for these interleukins in early DKD were not reported in the studies reviewed, so their diagnostic accuracy cannot yet be compared with that of the leading candidates.
C-Reactive Protein and High-Sensitivity C-Reactive Protein
C-reactive protein (CRP) is a hepatic acute-phase protein whose synthesis is principally driven by IL-6 and which is produced nonspecifically in response to inflammation, infection, and tissue injury.41,42
The high-sensitivity CRP (hs-CRP) assay quantifies the same protein but does so with greater analytical precision within the 0.5–10 mg/L concentration range, enabling identification of subtle baseline elevations in persons at risk of cardiovascular disease.43 In DKD, circulating CRP correlates with the severity and trajectory of inflammatory pathology, reflecting its dual role as both disease marker and contributor to disease mechanisms.43 Because CRP is not kidney-specific, its value for the early detection of DKD is limited, and no sensitivity or specificity data for this purpose were identified.
Monocyte Chemoattractant Protein-1
MCP-1 (also designated CCL2) is a chemokine with a central role in innate immune responses and tissue inflammation; its production by the diabetic kidney is a major determinant of intrarenal macrophage accumulation.39 Renal biopsy specimens from patients with DKD show MCP-1 elevation, and sustained hyperglycaemia drives its expression through oxidative stress.44 In T2DM, urinary MCP-1 reflects renal MCP-1 production and correlates with albuminuria, serum glycated albumin, urinary N-acetylglucosaminidase activity, and intrarenal CD68+ macrophage density.45 MCP-1 expression rises early in the disease course and continues to increase with progression, with the highest concentration in the tubular compartment.45 Urinary MCP-1 is significantly elevated in DKD patients with macroalbuminuria and microalbuminuria compared with normoalbuminuric patients and controls, and in women with type 1 diabetes a urinary threshold of 110 pg/mg achieved 92% sensitivity and 100% specificity for identifying early renal interstitial changes.39 MCP-1 is a convergence point for upstream mediators including angiotensin II and leptin,44 and urinary MCP-1 may be used to monitor therapeutic response, giving the molecule combined diagnostic and therapeutic relevance.
Other Inflammatory Candidates
Adipokines (adiponectin, leptin, and resistin), pentraxin-3, and fetuin-A have also been linked to metabolic and renal inflammation in diabetes.46 However, most of the available data come from experimental models or mixed chronic kidney disease populations, and diagnostic accuracy data for early DKD are lacking; these markers are therefore not discussed further in this review.
Tubular Injury Biomarkers
Kidney Injury Molecule-1
KIM-1 is a type I transmembrane protein composed of a 14-kDa membrane-bound fragment and a 90-kDa soluble ectodomain; it is expressed at negligible levels in the normal kidney but is markedly upregulated in the proximal tubule under injury.28,47 As a phosphatidylserine receptor, KIM-1 enables proximal tubular cells to clear apoptotic debris.28 KIM-1 has dual biological roles: acute upregulation moderates the innate immune response, while persistent expression promotes renal fibrosis and links the marker mechanistically to progressive CKD.28
In human diabetes, proximal tubular KIM-1 expression and its circulating and urinary concentrations rise at an early stage and predict the rate of disease progression.47,48 Urinary KIM-1 is higher in T2DM patients regardless of albuminuria status than in controls, identifying tubular injury before albuminuria appears; in type 1 diabetes, elevated urinary KIM-1 predicts subsequent increases in albuminuria over two-year follow-up.48–50 Plasma KIM-1 combined with sTNFR1 may signal progressive renal pathology earlier and with greater precision than eGFR or albumin excretion alone.50 In 80 patients with T2DM and eGFR above 60 mL/min/1.73 m2, the urinary KIM-1-to-creatinine ratio (cut-off 1.81 µg/g) identified moderately increased albuminuria with 67% sensitivity, 92% specificity, and an AUC of 0.84, whereas unadjusted urinary KIM-1 (cut-off 0.73 µg/L) reached 79% sensitivity but only 51% specificity (AUC 0.68).51
Urinary KIM-1 closely mirrors tissue expression and shows a positive linear relationship with interstitial fibrosis, tubular atrophy, and glomerulosclerosis; KIM-1-expressing tubules associate with macrophage aggregates and pre-fibrotic zones marked by elevated α-SMA.48,52 Urinary KIM-1 excretion reflects tubulointerstitial fibrosis more accurately than urinary NAG.53 Elevated baseline KIM-1 predicts adverse renal outcomes, with the highest KIM-1 quartile carrying increased odds of stage 3 CKD and rapid eGFR decline; therapeutic targeting of KIM-1-mediated proximal tubule injury has accordingly been proposed as a strategy to attenuate DKD progression.48,54
Neutrophil Gelatinase-Associated Lipocalin
NGAL (also known as lipocalin-2) is a 25-kDa protein of the lipocalin family secreted primarily by neutrophils, macrophages, and dendritic cells.55,56 Both urinary and plasma NGAL rise within two to six hours of acute kidney injury.57 NGAL expression is induced in both acute and chronic renal injury, and accumulating evidence supports it as a marker of both the presence and severity of CKD progression across diverse clinical settings.55 In diabetic nephropathy specifically, urinary NGAL is detectable at an early stage as a consequence of elevated serum glucose even before overt kidney injury, and both serum and urinary NGAL rise progressively with disease severity—including in normoalbuminuric patients—supporting its role as a pre-albuminuric indicator of tubular damage.56 In T2DM patients with preserved eGFR, urinary NGAL (cut-off 14.3 µg/L) identified moderately increased albuminuria with 80% sensitivity and 61% specificity (AUC 0.74); normalisation to creatinine (cut-off 28.3 µg/g) raised specificity to 87% at the cost of sensitivity (60%; AUC 0.71), and serum NGAL (cut-off 61.0 µg/L) showed 79% sensitivity and 61% specificity (AUC 0.69).51
Liver-Type Fatty Acid-Binding Protein
L-FABP is a 14-kDa lipid-binding protein expressed in hepatocytes and in both convoluted and straight portions of the human proximal tubule.58,59 By binding fatty acids and delivering them to mitochondria and peroxisomes for β-oxidation, L-FABP supports tubular-cell energy supply and confers protection against hydrogen-peroxide-induced oxidative stress; its expression is inducible under hypoxia through a hypoxia-inducible factor 1α response element.59 Urinary L-FABP is elevated in normoalbuminuric type 1 and type 2 diabetic patients relative to non-diabetic controls, suggesting that tubulointerstitial injury may precede glomerular pathology.54,58 Urinary L-FABP rises in proportion to DKD progression, correlates with the histological extent of fibrosis and macrophage infiltration, and is associated with cardiovascular events and anaemia.4 A meta-analysis of 13 studies confirmed higher urinary L-FABP in normoalbuminuric diabetic patients than in non-diabetic controls (standardised mean difference 1.72; 95% confidence interval, 0.44–2.99), but pooled sensitivity and specificity were not reported.4
N-Acetyl-β-D-Glucosaminidase
NAG is an intracellular lysosomal enzyme with its highest concentration in renal proximal tubules; as the most catalytically active lysosomal glycosidase in this compartment, its activity is closely correlated with tubular pathology.60,61 With a relative molecular mass of approximately 130,000, NAG cannot pass the glomerular filter; elevated urinary NAG therefore reflects release from disrupted tubular epithelial brush borders, with excreted quantity proportional to the magnitude of tubular injury.62 Urinary NAG rises in nephrotoxic drug exposure, delayed renal allograft function, chronic glomerular disease, and diabetic nephropathy, and in critically ill patients it can precede serum creatinine elevation by 12 hours to four days.61 In diabetic nephropathy, urinary NAG is elevated even in the absence of albuminuria and when serum creatinine does not differ from controls, supporting an early-diagnostic role.60 NAG elevation can, however, occur with NSAID use, rheumatoid arthritis, and analgesic exposure, requiring clinical contextualisation of any raised value.62 Sensitivity and specificity estimates for urinary NAG in early DKD were not available in the studies reviewed.
Low-Molecular-Weight Proteins: β2-Microglobulin and α1-Microglobulin
Low-molecular-weight (LMW) proteins—those with a molecular weight below 40 kDa—pass the glomerular filter with minimal restriction, but their urinary excretion normally remains negligible owing to efficient proximal tubular reabsorption.63 Impaired reabsorption produces urinary LMW protein excretion proportional to the severity of histological lesions, with elevated α1-microglobulin (A1M) and β2-microglobulin (B2M) associated with more pronounced proteinuria, higher serum creatinine, and greater tubulointerstitial injury.63 Urinary A1M is used as an indicator of the severity of renal tubulointerstitial fibrosis.64 In multiple logistic regression analyses, α1-microglobulin—but not IgG or 24-hour proteinuria—retained an independent association with progression to chronic renal failure, establishing A1M as a prognostically valuable tubular marker beyond conventional proteinuria measurements.63
Glomerular, Fibrotic, and Podocyte Biomarkers
Transforming Growth Factor-β
TGF-β is among the most firmly established pathogenic drivers of diabetic nephropathy, implicated across experimental and clinical investigations.65,66 Of its three mammalian isoforms, TGF-β1 is most consistently implicated in renal fibrosis.67 Plasma TGF-β1 rises in both type 1 and type 2 diabetes and is further elevated in patients who develop nephropathy, correlating with the degree of renal impairment; urinary TGF-β is also raised in affected individuals, consistent with active intrarenal signalling.65 Renal biopsies from diabetic nephropathy patients show markedly elevated glomerular TGF-β1 mRNA and enhanced immunoreactivity for all three isoforms across glomerular and tubulointerstitial compartments. Persistent TGF-β/Smad3 overactivation is essential for the pro-fibrotic tissue phenotype and drives renal cellular injury via both canonical and non-canonical signalling arms; among TGF-β-induced extracellular matrix proteins are collagen I and fibronectin.66,67
Collagen IV
Type IV collagen is the predominant structural constituent of the glomerular basement membrane and mesangial matrix, existing as a heterotrimer of up to six genetically distinct α-chains.68 The morphological hallmark of diabetic nephropathy is excess extracellular matrix accumulation within the mesangium and along basement membranes, and collagen IV is quantitatively increased in diabetic glomerular injury.69 Urinary collagen IV rises progressively as diabetic nephropathy advances and is significantly elevated in both normoalbuminuric and microalbuminuric diabetic patients relative to controls; values correlate with urinary albumin but not with glycosylated haemoglobin, and are higher in microalbuminuric than in normoalbuminuric cohorts (P < 0.01), supporting serial measurement as a clinically meaningful marker of early renal injury.68,69
Connective Tissue Growth Factor
CCN2, more commonly known as connective tissue growth factor (CTGF), is a 38-kDa cysteine-rich member of the CCN family, expressed most abundantly in renal tissue where excess production drives fibrosis.70 In mesangial cells, CTGF expression is induced by elevated glucose, mechanical loading, and TGF-β.71 CTGF suppresses matrix degradation through TIMP-1 upregulation, and podocyte-targeted overexpression of CCN2 amplifies proteinuria and mesangial expansion in murine models.70 In healthy individuals, urinary CCN2 concentrations are low but rise approximately sevenfold in streptozotocin-diabetic animals.71 Its diagnostic accuracy in early human DKD remains to be established.
Podocyte Injury Biomarkers: Nephrin, Podocin, and Podocalyxin
The structural integrity of glomerular podocytes depends on three key proteins—nephrin, podocin, and podocalyxin—each serving as a measurable indicator of glomerular damage.72 Nephrin, encoded by NPHS1, is the essential molecular constituent of the slit diaphragm situated between opposing podocyte foot processes, and its expression is diminished across multiple glomerular conditions including diabetic nephropathy; urinary nephrin has been detected in 82% of T2DM patients with normoalbuminuria, with ROC analysis indicating a cumulative predictive probability of 96% for diabetic nephropathy and an inverse relationship with GFR.73 Podocin, encoded by NPHS2, functions as the molecular partner of nephrin, binding its cytoplasmic tail; urinary sediment podocin mRNA is markedly elevated in normoalbuminuric diabetic patients relative to age-matched healthy controls, preceding microalbuminuria detection.72 Podocalyxin, a sialic-acid-rich apical glycoprotein maintaining glomerular charge selectivity, is diminished in renal tissue in diabetic nephropathy while the urinary podocalyxin-to-creatinine ratio rises correspondingly—including in diabetic patients without detectable albuminuria or microalbuminuria.72,74
Oxidative Stress Biomarkers
A number of biomarkers have been investigated for their ability to quantify oxidative burden in patients with DKD; the two with the most direct relevance to early kidney injury are discussed below.
8-Hydroxy-2′-Deoxyguanosine
The formation of 8-hydroxy-2′-deoxyguanosine (8-OHdG) takes place when guanine residues in DNA are hydroxylated at the 8-position as a result of excessive ROS accumulation; this makes it a direct molecular indicator that reflects genomic oxidative damage rather than serving as a non-specific measure of general cellular stress.75,76 Both in serum and in urine, 8-OHdG concentrations have been found to be significantly higher in diabetic patients as compared to non-diabetic controls, and the degree of elevation shows a progressive increase corresponding to the stage of albuminuria.75
Concentrations in urine exceed those in blood by approximately tenfold, suggesting that the kidney itself, through NOX4-driven ROS production, constitutes a primary site where 8-OHdG is generated.75 In DKD patients, circulating 8-OHdG was reported at 4.6 ± 0.7 ng/mL versus 4.0 ± 0.8 ng/mL in those without renal dysfunction (p = 0.002), and each 1 ng/mL increment corresponded to an 11.5 mL/min/1.73 m2 reduction in GFR.76
Urinary F2-Isoprostanes
F2-isoprostanes arise from non-enzymatic peroxidation of membrane arachidonic acid by ROS and serve as dependable indices of in vivo oxidative burden.77 In streptozotocin-induced diabetic rats, plasma and urinary F2-isoprostanes rose within seven days of diabetes induction, supporting oxidative stress as an early contributor to nephropathic change.78 Urinary F2-isoprostanes show reasonable within-individual stability in first-morning void specimens and are recommended, alongside 8-oxodG, as a preferred panel for longitudinal monitoring of oxidative status.77 Human diagnostic accuracy data for early DKD are still lacking.
Other Emerging Biomarkers
Cystatin C
Cystatin C is a 13-kDa non-glycosylated basic protein of the cystatin superfamily, produced at a steady rate by all nucleated cells and freely filtered at the glomerulus; its production is largely independent of muscle mass—a major confounder of creatinine-based estimates—making it a more dependable endogenous surrogate of GFR.79,80 In DKD, ROC analysis gave an AUC of 0.76 for cystatin C versus 0.66 for serum creatinine, and abnormal cystatin C values were present in 91% of participants compared with 63% showing abnormal creatinine; a strong negative correlation between cystatin C and eGFR (r = –0.552) reinforces the directional relationship.79,80 In T2DM patients with preserved eGFR, a serum cystatin C cut-off of 1.09 mg/L identified moderately increased albuminuria with 68% sensitivity and 90% specificity (AUC 0.78).51 A multi-marker panel combining cystatin C with homocysteine and microalbuminuria achieved sensitivity 82.0%, specificity 86.7%, and AUC 0.928, substantially outperforming the individual markers.81 A combined creatinine–cystatin C eGFR equation with race-free recalibration improves estimation accuracy and narrows CKD-prevalence disparities across subgroups.82
Cluster of Differentiation 146 as a Marker of Endothelial Dysfunction
Cluster of differentiation 146 (CD146) is a 113-kDa transmembrane glycoprotein constitutively expressed in vascular endothelium and concentrated at inter-endothelial junctions; its soluble form, sCD146, is shed into the circulation through proteolytic processing.83 In diabetic nephropathy, CD146 expression is substantially upregulated in glomerular endothelial cells relative to controls, and plasma sCD146 has been reported to reflect disease severity at CKD stages 1–3 better than UACR.83 This finding awaits independent validation, and diagnostic cut-off values, sensitivity, and specificity have not yet been established.
Vascular Endothelial Growth Factor
Vascular endothelial growth factor A (VEGF-A) is produced in the kidney mainly by podocytes and tubular epithelial cells and signals through VEGFR-2 on glomerular endothelium.84 Under diabetic conditions, VEGF and its receptors are upregulated, VEGF overexpression raises glomerular permeability and induces pro-inflammatory and pro-fibrotic mediators, and VEGF expression is significantly higher in diabetic nephropathy patients than in controls, correlating with inflammatory mediator concentrations and indices of renal functional impairment.85 Its diagnostic accuracy for early DKD has not been established.
Circulating MicroRNAs as Novel Biomarkers
Circulating microRNAs (miRNAs)—small non-coding RNAs stabilised in biological fluids through exosome encapsulation or protein complexation—are accessible in both blood and urine and may change before conventional indicators such as albuminuria.86,87 A meta-analysis of nine studies (655 patients with early DKD and 664 controls) reported a pooled sensitivity of 76%, a pooled specificity of 74%, and a summary AUC of 0.79; urine-derived miRNAs were more sensitive than blood-derived miRNAs (82% versus 68%), and combining several miRNAs or adding clinical variables improved accuracy.87 miR-21 is dramatically upregulated in plasma, urine, and renal tissue of DKD patients and intensifies as the disease advances; at a plasma concentration threshold of 0.01, miR-21 achieved a sensitivity of 94.1% and a specificity of 100%—surpassing the performance of the ACR at 45 mg/g.88 miR-192 shows directionally opposing patterns between compartments: low serum expression characterises early-stage DKD and may serve as a predictive signal, whereas elevated concentrations in renal tissue and urine are indicative of disease progression.89 miR-216a and miR-377 display aberrant expression during the early phases of DKD with modification as the condition advances, and miR-4534 has been proposed as an emerging candidate biomarker for T2DM DKD progression.87,90
Comparative Performance and Clinical Utility
Biomarkers with the Strongest Evidence for Early Diabetic Kidney Disease
From among the various biomarkers studied, a few have stood out as particularly strong candidates for the early identification of diabetic nephropathy, mainly because they demonstrate diagnostic superiority when compared with serum creatinine and microalbuminuria.3,51 Serum cystatin C consistently outperforms both traditional markers for detecting early glomerular filtration impairment across T2DM populations. Serum and urinary NGAL show pre-microalbuminuric elevations; serum NGAL above 61 µg/L was the sole marker significantly associated with a higher rate of eGFR decline in one longitudinal study, and urinary NGAL-to-creatinine ratio correlates significantly with rising UACR values.51 KIM-1 shows robust discriminatory capacity, with the urinary KIM-1-to-creatinine ratio achieving the highest AUC among the markers evaluated for distinguishing patients with and without moderately increased albuminuria (AUC 0.84; sensitivity 67%, specificity 92%).51,91 E-cadherin demonstrated a near-perfect AUC of 0.998 for diagnosing established microalbuminuria,3 and urinary BBOX1 mRNA—predominantly from detached tubular epithelial cells—achieved an AUC of 0.762 for discriminating non-end-stage DKD from controls.92 Diabetic nephropathy may progress in the absence of microalbuminuria, and its advancement correlates most closely with the extent of tubulointerstitial rather than glomerular injury, underscoring the clinical priority of identifying tubular damage biomarkers at the earliest stage.91 The reported sensitivity, specificity, and AUC values of the main candidates are summarised in Table 2. Because study populations, target conditions, assays, and cut-off values differ, these figures indicate the range of reported performance rather than allowing a strict ranking of biomarkers.
Table 2. Reported diagnostic performance of candidate biomarkers for early diabetic kidney disease
| Biomarker (sample) | Population and target condition | Cut-off | Sensitivity, % | Specificity, % | AUC |
|---|---|---|---|---|---|
| Serum sTNFR137 | T2DM (n = 416); >30% eGFR decline, mean follow-up 5.5 y | 12.48 pg/dL | 66 | 75 | 0.73 |
| Urinary KIM-1/Cr51 | T2DM with eGFR >60 mL/min/1.73 m2 (n = 80); moderately increased albuminuria | 1.81 µg/g | 67 | 92 | 0.84 |
| Urinary KIM-151 | Same cohort and target | 0.73 µg/L | 79 | 51 | 0.68 |
| Urinary NGAL51 | Same cohort and target | 14.3 µg/L | 80 | 61 | 0.74 |
| Urinary NGAL/Cr51 | Same cohort and target | 28.3 µg/g | 60 | 87 | 0.71 |
| Serum NGAL51 | Same cohort and target | 61.0 µg/L | 79 | 61 | 0.69 |
| Serum cystatin C51 | Same cohort and target | 1.09 mg/L | 68 | 90 | 0.78 |
| Serum cystatin C79,80 | DKD (serum creatinine AUC 0.66 for comparison) | NR | NR | NR | 0.76 |
| Cystatin C + homocysteine + microalbumin81 | Early diabetic nephropathy | NR | 82.0 | 86.7 | 0.928 |
| Urinary MCP-139 | Women with type 1 diabetes; early renal interstitial change | 110 pg/mg | 92 | 100 | NR |
| Urinary mindin20 | T2DM; podocyte injury before overt proteinuria | NR | 68 | 87.0 | 0.87 |
| Urinary nephrin73 | T2DM; positive in 82% of normoalbuminuric patients (predictive probability 96%) | NR | NR | NR | NR |
| Plasma miR-2188 | DKD; outperformed ACR at 45 mg/g | 0.01 | 94.1 | 100 | NR |
| Circulating and urinary miRNAs, pooled (9 studies)87 | Early DKD (655 patients, 664 controls) | Study-specific | 76 | 74 | 0.79 |
| Urinary L-FABP, meta-analysis (13 studies)4 | Normoalbuminuric diabetes versus non-diabetic controls | NR | NR | NR | NR (SMD 1.72) |
| Urinary E-cadherin3 | Established microalbuminuria | NR | NR | NR | 0.998 |
| Urinary BBOX1 mRNA92 | Non-end-stage DKD versus controls | NR | NR | NR | 0.762 |
| Four-marker panel93 | Two-year DKD onset (prospective) | NA | NR | NR | 0.873 |
| Optimised multi-marker panel94 | Renal progression | NA | NR | NR | C-statistic 0.835 → 0.896 |
| Serum metabolite XGBoost model49 | DKD screening | NA | NR | NR | 0.966 |
Values are taken from the cited studies; because populations, target conditions, assays, and cut-off values differ, they indicate the range of reported performance and are not directly comparable. Abbreviations: ACR, albumin-to-creatinine ratio; AUC, area under the receiver operating characteristic curve; Cr, creatinine; DKD, diabetic kidney disease; eGFR, estimated glomerular filtration rate; KIM-1, kidney injury molecule-1; L-FABP, liver-type fatty acid-binding protein; MCP-1, monocyte chemoattractant protein-1; miRNA, microRNA; NA, not applicable; NGAL, neutrophil gelatinase-associated lipocalin; NR, not reported; SMD, standardised mean difference; sTNFR1, soluble tumour necrosis factor receptor 1; T2DM, type 2 diabetes mellitus; XGBoost, extreme gradient boosting.
Head-to-Head Comparisons of Leading Candidates
Direct comparative studies of tubular biomarkers reveal shared utility and meaningful functional distinctions among NGAL, KIM-1, and emerging candidates.95 In normoalbuminuric T2DM patients, urinary NGAL is already raised and increases progressively across microalbuminuric and macroalbuminuric stages; urinary KIM-1 follows a similar pattern, confirming that proximal tubular injury precedes the crossing of albuminuria thresholds.95 Both markers are also augmented in hyperfiltrating T2DM patients compared with those showing normal filtration, consistent with a deleterious effect of hyperfiltration on the proximal tubule at the earliest detectable stages.95 A functional distinction separates the two markers: urinary NGAL correlates positively with UACR and inversely with eGFR, whereas urinary KIM-1 shows no significant variation across diabetic subgroups and is not meaningfully coupled to either UACR or eGFR, suggesting that NGAL tracks glomerular functional change more closely while KIM-1 captures a more compartmentalised dimension of tubular damage.96 Beyond tubular markers, circulating TNFR1 and TNFR2 are predictive of ESRD in T2DM, and the plasma TGF-β to BMP-7 ratio has emerged as a novel inflammatory–fibrotic axis.96
Incremental Value Over Traditional Markers
Microalbuminuria, proteinuria, and eGFR loss each have well-recognised prognostic constraints: a subset of diabetic patients progresses to renal impairment before microalbuminuria becomes detectable, while others with confirmed albuminuria never progress—rendering these markers imperfect instruments in both directions.96,97 Certain tubular injury biomarkers outperform microalbuminuria at the earliest nephropathic stages, operating independently of glomerular permeability defects; a urinary proteomic classifier identified normoalbuminuric individuals who subsequently developed macroalbuminuria five years later, with predictive capacity exceeding that of microalbuminuria alone.96 Urinary epidermal growth factor expressed as a ratio to creatinine (uEGF/Cr) was independently associated with incident CKD stage 3 and rapid renal functional decline (>5% per annum) in T2DM patients without baseline albuminuria or reduced renal function.97 Multi-omics and machine-learning approaches extend predictive capacity further: an XGBoost model constructed from serum metabolites achieved an AUC of 0.966 for DKD screening, surpassing earlier models with AUCs of 0.79–0.93.49 The CKD273 urinary peptide signature has demonstrated superior CKD detection across several-thousand-patient validation studies, and the Kidney Risk Inflammatory Signature—a panel of 17 inflammatory proteins enriched for TNF-receptor superfamily members—significantly predicts ten-year ESRD risk.98
Biomarker Panels versus Single Markers
The multifactorial pathophysiology of DKD makes the pursuit of a single universally reliable biomarker an inadequate strategy, and evidence increasingly favours multi-marker panels for early detection, risk stratification, and therapeutic monitoring.94,99 A methodological limitation pervading the biomarker literature is the failure of many studies to rigorously evaluate the marginal predictive gain a novel marker adds beyond routine clinical data.94 Panel-based approaches have nonetheless demonstrated measurable superiority over single-marker models: the C-statistic for renal progression prediction rose from 0.835 to 0.896 following incorporation of an optimised panel, with further refinement achievable through selection of markers with low mutual correlation.94 In a prospective evaluation of seven candidates, a four-marker model achieved an AUC of 0.873 for two-year DKD-onset prediction, outperforming models based on classical indicators such as eGFR combined with UACR; among individual candidates assessed, urinary MCP-1 ranked highest for both cross-sectional DKD diagnosis and incident DKD prediction, with further enhancement when combined with clinical variables.93 Soluble TNF-α receptors 1 and 2 have emerged from multiple independent studies as among the most robustly validated predictors of rapid renal decline.99 Optimal panels should be evaluated against hard endpoints such as doubling of serum creatinine, onset of ESRD, or renal death, and future panel optimisation would benefit from a personalised strategy accounting for the heterogeneity of DKD phenotypes and differential rates of progression.94
Gaps, Challenges, and Future Directions
Lack of Standardised Assays and Cut-off Values
Clinical translation of DKD biomarkers is complicated by several biological and methodological challenges. Urinary albumin excretion shows intraindividual variability of 4% to 103% and is further distorted by fever, infection, and hypertension.9,100
The natural fluctuation that occurs in eGFR and UACR values introduces classification error, and as a consequence there exists a risk of assigning patients to disease categories that do not accurately represent their true renal status.8 GFR estimation is additionally constrained when values fall within the normal and elevated ranges, limiting early-decline detection.11 Confirmatory repeat measurement at least three months apart is recommended before finalising clinical decisions.19 Beyond measurement challenges, considerable scientific and technological effort is still required to establish the diagnostic validation, cross-platform standardisation, and analytical infrastructure necessary before novel biomarker panels can enter routine clinical workflows.99
Limited Validation in Normoalbuminuric Patients
A particularly consequential gap concerns diabetic patients whose renal function declines without detectable albuminuria—a non-albuminuric phenotype now reported to account for 40% to 70% of diabetic CKD.8 Because this form is not accompanied by proteinuria, it is frequently overlooked under frameworks retaining albuminuria as the primary screening criterion; UACR and eGFR both show poor sensitivity in this setting.9,100 Non-albuminuric DKD occurs disproportionately in older patients and in women.10 Sensitive and specific biomarkers validated specifically in this subgroup remain scarce, and prognostic candidates have rarely been tested against hard regulatory endpoints such as serum creatinine doubling, onset of ESRD, or renal death.94
Underrepresentation of South Asian and Indian Populations
CKD-related morbidity and mortality vary substantially by income level and geographic setting, reflecting inequities in healthcare access, early detection capacity, and availability of renal replacement therapies.17 Diagnostic estimation tools have exhibited inter-group disparities, and adoption of race-free combined creatinine–cystatin C equations has been proposed as a meaningful step toward reducing differences in estimated CKD prevalence.82 Published Indian data on emerging DKD biomarkers in T2DM and CKD populations remains comparatively sparse relative to their clinical importance in this patient demographic. The current platform availability, sample requirements, and analytical stability of these biomarkers in Indian clinical biochemistry laboratories are summarised in Table 3.
Table 3. Assay landscape for biomarker measurement in Indian clinical biochemistry laboratories. Abbreviations: CDSCO, Central Drugs Standard Control Organisation; CE-MS, capillary electrophoresis–mass spectrometry; Cr, creatinine; ELISA, enzyme-linked immunosorbent assay; IVD, in vitro diagnostic; LC-MS/MS, liquid chromatography–tandem mass spectrometry; POC, point of care; RT, room temperature; RT-qPCR, reverse-transcription quantitative polymerase chain reaction.
| Biomarker | Platform | Availability in India | Sample | Stability |
|---|---|---|---|---|
| Cystatin C | Turbidimetry; nephelometry | Yes — Roche, Siemens, Beckman, Abbott widely available | 50–100 µL serum | 4°C ≥7 d; –80°C long-term |
| sTNFR1/2 | Sandwich ELISA | Imported research-grade kits; limited CDSCO-listed IVD | 50–100 µL serum | Stable –80°C |
| KIM-1 | Sandwich ELISA | Research-grade ELISA kits via import | 200–500 µL urine | Stable –80°C; normalise to Cr |
| NGAL | ELISA; turbidimetric; POC | BioPorto reagent imported; POC available | 100 µL serum or 500 µL urine | 4°C ≤48 h; –80°C long-term |
| L-FABP | ELISA | Research-grade; limited routine availability | 500 µL urine | Stable –80°C |
| NAG | Colorimetric | Kits from Randox and others via Indian distributors | 500 µL urine | Unstable at RT; process <24 h or freeze |
| hs-CRP | Nephelometry; turbidimetry | Widely available | 100 µL serum | Stable |
| IL-6, TNF-α, IL-18 | ELISA; chemiluminescence | ELISA imported; Roche Elecsys IL-6 in some centres | 100 µL serum | Stable –80°C |
| MCP-1 | ELISA | Research-grade only | 500 µL urine | Stable –80°C |
| 8-OHdG | Competitive ELISA; LC-MS/MS | Research ELISA imported; LC-MS in few centres | 500 µL urine/serum | Protect from light; –80°C |
| Nephrin | ELISA | Research-grade only | 500 µL urine | Stable –80°C |
| CD146 | ELISA | Research-grade only | 100 µL plasma | Stable –80°C |
| VEGF-A | ELISA; chemiluminescence | Available via import; in oncology workflows | 100 µL serum | Stable –80°C |
| miR-21/miR-192 | RT-qPCR; digital PCR | Limited to specialist centres | 500 µL–1 mL plasma/urine | RNA stabiliser required; –80°C |
| CKD273 | CE-MS | Not available in Indian routine labs | 10 mL urine | 4°C 3 d; –80°C long-term |
Need for Longitudinal, Multicentre Studies
Translation of novel biomarkers from experimental identification to clinical deployment requires longitudinal data that quantify the lead time a candidate marker provides ahead of clinical milestones; urinary proteomic profiling has already identified renal alterations up to five years before the emergence of stage A2 albuminuria, although broad ethnic and clinical validation remains outstanding.94,96 Most existing investigations have follow-up durations insufficient to link early biomarker shifts with hard regulatory endpoints. Certain markers, including urinary F2-isoprostanes, have been recognised for chemical stability and reasonable within-individual consistency over time, lending them to longitudinal biomonitoring—though cross-site confirmation of such stability is required before universal cut-off values can be established.77 Adequately powered, geographically representative multicentre studies are uniquely positioned to simultaneously assay a broad range of correlated candidates and rigorously estimate each marker’s independent prognostic contribution across the heterogeneity of DKD phenotypes.94,98
From Discovery to Clinical Practice
Progress toward routine clinical adoption faces interrelated research, infrastructural, and health-systems challenges. Standardisation remains a formidable barrier: diagnostic validation frameworks, cross-platform protocols, and analytical infrastructure are still needed to transition novel panels from research settings into routine workflows.99 Ideal prognostic panels must ultimately be evaluated against hard endpoints—serum creatinine doubling, onset of ESRD, or renal death—rather than intermediate surrogates that inadequately reflect the full trajectory of nephropathic deterioration.94 Cost and accessibility considerations further constrain the population-level applicability of sensitive markers, with cystatin C being a notable example.79 Despite established screening protocols, DKD remains substantially underdiagnosed, and the incorporation of new markers must yield tangible improvements to existing workflows rather than simply augmenting their complexity.91 Future priorities should centre on developing personalised biomarker selection strategies that accommodate DKD phenotype heterogeneity and the variable rates of progression observed across patient subgroups.99
Conclusion
Among candidate biomarkers evaluated for early detection and risk stratification of diabetic nephropathy, sTNFR1, KIM-1, and NGAL are most consistently supported across independent investigations. Each signals renal injury before microalbuminuria or eGFR decline becomes detectable—a clinically critical window, since up to 50% of functioning nephron mass may already be lost by the time moderately elevated albuminuria or an eGFR below 60 mL/min/1.73 m2 first becomes measurable.
sTNFR1 predicts ESRD independently of baseline UACR and eGFR, and in head-to-head comparison against the combined UACR–eGFR model showed non-inferior discriminatory performance with an AUC of 0.73 versus 0.71 (sensitivity 66% and specificity 75% at 12.48 pg/dL); direct measurement via commercial ELISA is a practical advantage over calculated eGFR.37,99 KIM-1 is an early indicator of proximal tubular injury, with urinary concentrations elevated irrespective of albuminuric status and correlating with interstitial fibrosis, tubular atrophy, and glomerulosclerosis; the urinary KIM-1-to-creatinine ratio identified moderately increased albuminuria with 67% sensitivity and 92% specificity, and the highest KIM-1 quartile predicts rapid eGFR decline and incident stage 3 CKD.48,51 NGAL detects tubular injury at the normoalbuminuric stage; urinary NGAL showed 80% sensitivity but only 61% specificity for moderately increased albuminuria, and serum NGAL above 61 µg/L was identified as the sole marker significantly associated with a higher eGFR decline rate in one longitudinal study.51 NGAL and KIM-1 are complementary rather than interchangeable: NGAL couples more strongly to glomerular functional change, whereas KIM-1 captures a more compartmentalised dimension of tubular damage.96
Clinical practice should move beyond traditional albuminuria-based screening toward a molecularly informed approach. sTNFR1, KIM-1, and NGAL warrant prioritisation given their evidential support and capacity to identify renal risk at an earlier stage than conventional indicators.51,99 Tubular injury markers including L-FABP and NAG merit consideration for early screening alongside these front-line candidates.91,96 Particular attention is required for the non-albuminuric DKD phenotype, which now accounts for 40% to 70% of diabetic CKD but is inadequately detected by current screening tools.8,9 Future research should rigorously quantify the marginal predictive gain a novel marker provides over routine clinical data, evaluate multi-marker panels against single biomarkers with selection for low mutual correlation, and assess all candidates against hard regulatory endpoints rather than intermediate surrogates.93,94 Standardisation of assays, clinical validation across diverse populations (with explicit attention to the South Asian and Indian context addressed in Section 11.3), and integration into existing diagnostic workflows remain essential prerequisites for translating promising candidates into routine clinical use.
Statements and Declarations
- Funding
- The authors did not receive support from any organisation for the submitted work. No funding was received to assist with the preparation of this manuscript.
- Clinical Trial Number
- Clinical trial number: not applicable. This article is a narrative review of previously published peer-reviewed literature; it does not report a clinical trial, and no trial registration was therefore required. Mentions of NLRP3 within the manuscript refer to the NLRP3 inflammasome, a cytosolic protein complex implicated in the pathogenesis of diabetic kidney disease, and not to any clinical trial registry identifier.
- Competing Interests
- The authors have no relevant financial or non-financial interests to disclose.
- Ethics Approval
- Not applicable. This article is a narrative review of previously published peer-reviewed literature and did not involve any new studies of human or animal subjects performed by any of the authors.
- Consent to Participate
- Not applicable.
- Consent for Publication
- Not applicable.
- Data Availability
- Data sharing is not applicable to this article as no datasets were generated or analysed during the current review. All sources are available in the cited published literature.
- Authors’ Contributions
- Conceptualisation: Anupriya Velu, Palani Selvam Mohanraj. Literature search and data extraction: Anupriya Velu, Anupama Ojha. Critical analysis and interpretation: Palani Selvam Mohanraj, Suresh K Srinivasan, Vinoth Rajendran. Writing - original draft preparation: Anupriya Velu. Writing - review and editing: Palani Selvam Mohanraj, Suresh K Srinivasan, Anupama Ojha, Vinoth Rajendran. Supervision: Palani Selvam Mohanraj. All authors read and approved the final version of the manuscript.
Abbreviations
- ACR: Albumin-to-creatinine ratio
- AGE: Advanced glycation end product
- AUC: Area under the receiver operating characteristic curve
- CKD: Chronic kidney disease
- CRP: C-reactive protein
- CTGF: Connective tissue growth factor (CCN2)
- DKD: Diabetic kidney disease
- eGFR: Estimated glomerular filtration rate
- ELISA: Enzyme-linked immunosorbent assay
- ESRD: End-stage renal disease
- GFR: Glomerular filtration rate
- hs-CRP: High-sensitivity C-reactive protein
- IL: Interleukin
- KIM-1: Kidney injury molecule-1
- L-FABP: Liver-type fatty acid-binding protein
- MCP-1: Monocyte chemoattractant protein-1
- miRNA: MicroRNA
- NAG: N-acetyl-β-D-glucosaminidase
- NGAL: Neutrophil gelatinase-associated lipocalin
- ROS: Reactive oxygen species
- sTNFR: Soluble tumour necrosis factor receptor
- T2DM: Type 2 diabetes mellitus
- TGF-β: Transforming growth factor β
- TNF-α: Tumour necrosis factor α
- UACR: Urinary albumin-to-creatinine ratio
- VEGF: Vascular endothelial growth factor
References
- Kim KS, Lee JS, Park JH, et al. Identification of novel biomarker for early detection of diabetic nephropathy. Biomedicines. 2021;9(5):457. doi:10.3390/biomedicines9050457
- Karimi F, Moazamfard M, Taghvaeefar R, et al. Early detection of diabetic nephropathy based on urinary and serum biomarkers: an updated systematic review. Adv Biomed Res. 2024;13:104. doi:10.4103/abr.abr_461_23
- Thipsawat S. Early detection of diabetic nephropathy in patient with type 2 diabetes mellitus: a review of the literature. Diab Vasc Dis Res. 2021;18(6):14791641211058856. doi:10.1177/14791641211058856
- Zhang L, Xue S, Wu M, Dong D. Performance of urinary liver-type fatty acid-binding protein in diabetic nephropathy: a meta-analysis. Front Med (Lausanne). 2022;9:914587. doi:10.3389/fmed.2022.914587
- Shetty S, Suvarna R, Awasthi A, Bhojaraja MV, Pappachan JM. Emerging biomarkers and innovative therapeutic strategies in diabetic kidney disease: a pathway to precision medicine. Diagnostics (Basel). 2025;15(8):973. doi:10.3390/diagnostics15080973
- Genitsaridi I, Salpea P, Salim A, et al. 11th edition of the IDF Diabetes Atlas: global, regional, and national diabetes prevalence estimates for 2024 and projections for 2050. Lancet Diabetes Endocrinol. 2026;14(2):149-156. doi:10.1016/S2213-8587(25)00299-2
- Kowalski A, Krikorian A, Lerma EV. Diabetic nephropathy for the primary care provider: new understandings on early detection and treatment. Ochsner J. 2014;14(3):369-379.
- Korbut AI, Klimontov VV, Vinogradov IV, Romanov VV. Risk factors and urinary biomarkers of non-albuminuric and albuminuric chronic kidney disease in patients with type 2 diabetes. World J Diabetes. 2019;10(11):517-533. doi:10.4239/wjd.v10.i11.517
- An N, Wu B, Yang Y, Huang Z, Feng J. Re-understanding and focusing on normoalbuminuric diabetic kidney disease. Front Endocrinol (Lausanne). 2022;13:1077929. doi:10.3389/fendo.2022.1077929
- Green JB, Mottl AK, Bakris G, et al. Design of the Combination Effect of Finerenone and Empagliflozin in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE). Nephrol Dial Transplant. 2023;38(4):894-903. doi:10.1093/ndt/gfac198
- Hojs R, Ekart R, Bevc S, Hojs N. Biomarkers of renal disease and progression in patients with diabetes. J Clin Med. 2015;4(5):1010-1024. doi:10.3390/jcm4051010
- Park J, Mehrotra R, Rhee CM, et al. Serum creatinine level, a surrogate of muscle mass, predicts mortality in peritoneal dialysis patients. Nephrol Dial Transplant. 2013;28(8):2146-2155. doi:10.1093/ndt/gft213
- Boss GR, Seegmiller JE. Age-related physiological changes and their clinical significance. West J Med. 1981;135(6):434-440.
- Rayego-Mateos S, Rodrigues-Diez R, Morgado-Pascual JL, et al. Role of epidermal growth factor receptor (EGFR) and its ligands in kidney inflammation and damage. Mediators Inflamm. 2018;2018:8739473. doi:10.1155/2018/8739473
- Samsu N. Diabetic nephropathy: challenges in pathogenesis, diagnosis, and treatment. Biomed Res Int. 2021;2021:1497449. doi:10.1155/2021/1497449
- Tobe SW, McFarlane PA, Naimark DM. Microalbuminuria in diabetes mellitus. CMAJ. 2002;167(5):499-503.
- Cockwell P, Fisher LA. The global burden of chronic kidney disease. Lancet. 2020;395(10225):662-664. doi:10.1016/S0140-6736(19)32977-0
- Futrakul N, Futrakul P. Biomarker for early renal microvascular and diabetic kidney diseases. Ren Fail. 2017;39(1):505-511. doi:10.1080/0886022X.2017.1323647
- Rao IR, Bangera A, Nagaraju SP, et al. Chronic kidney disease of unknown aetiology: a comprehensive review of a global public health problem. Trop Med Int Health. 2023;28(8):588-600. doi:10.1111/tmi.13913
- Martins ALMDS, Bernardes AB, Ferreira VA, et al. In situ assessment of Mindin as a biomarker of podocyte lesions in diabetic nephropathy. PLoS One. 2023;18(5):e0284789. doi:10.1371/journal.pone.0284789
- Khanijou V, Zafari N, Coughlan MT, MacIsaac RJ, Ekinci EI. Review of potential biomarkers of inflammation and kidney injury in diabetic kidney disease. Diabetes Metab Res Rev. 2022;38(6):e3556. doi:10.1002/dmrr.3556
- Lv Y, Ye C, Li Z, et al. Tubular injury in diabetic kidney disease: early diagnosis and intervention strategies. Diabetes Metab Res Rev. 2025;41(7):e70098. doi:10.1002/dmrr.70098
- Młynarska E, Buławska D, Czarnik W, et al. Novel insights into diabetic kidney disease. Int J Mol Sci. 2024;25(18):10222. doi:10.3390/ijms251810222
- Thomas MC, Brownlee M, Susztak K, et al. Diabetic kidney disease. Nat Rev Dis Primers. 2015;1:15018. doi:10.1038/nrdp.2015.18
- Xue R, Xiao H, Kumar V, et al. The molecular mechanism of renal tubulointerstitial inflammation promoting diabetic nephropathy. Int J Nephrol Renovasc Dis. 2023;16:241-252. doi:10.2147/IJNRD.S436791
- Zeni L, Norden AGW, Cancarini G, Unwin RJ. A more tubulocentric view of diabetic kidney disease. J Nephrol. 2017;30(6):701-717. doi:10.1007/s40620-017-0423-9
- Fiseha T, Tamir Z. Urinary markers of tubular injury in early diabetic nephropathy. Int J Nephrol. 2016;2016:4647685. doi:10.1155/2016/4647685
- Bonventre JV. Can we target tubular damage to prevent renal function decline in diabetes? Semin Nephrol. 2012;32(5):452-462. doi:10.1016/j.semnephrol.2012.07.008
- Feng L, Feng YY, Ren Q, Fu P, Ma L. Mesangial cells in diabetic kidney disease: from mechanisms to therapeutic implications. Int J Biol Sci. 2025;21(11):4762-4781. doi:10.7150/ijbs.114907
- Thomas HY, Ford Versypt AN. Pathophysiology of mesangial expansion in diabetic nephropathy: mesangial structure, glomerular biomechanics, and biochemical signaling and regulation. J Biol Eng. 2022;16(1):19. doi:10.1186/s13036-022-00299-4
- Fogo AB. Causes and pathogenesis of focal segmental glomerulosclerosis. Nat Rev Nephrol. 2015;11(2):76-87. doi:10.1038/nrneph.2014.216
- Rosenberg AZ, Kopp JB. Focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2017;12(3):502-517. doi:10.2215/CJN.05960616
- An Y, Xu BT, Wan SR, et al. The role of oxidative stress in diabetes mellitus-induced vascular endothelial dysfunction. Cardiovasc Diabetol. 2023;22(1):237. doi:10.1186/s12933-023-01965-7
- Naderi-Meshkin H, Setyaningsih WAW. Endothelial cell dysfunction: onset, progression, and consequences. Front Biosci (Landmark Ed). 2024;29(6):223. doi:10.31083/j.fbl2906223
- Carlsson AC, Larsson TE, Helmersson-Karlqvist J, Larsson A, Lind L, Ärnlöv J. Soluble TNF receptors and kidney dysfunction in the elderly. J Am Soc Nephrol. 2014;25(6):1313-1320. doi:10.1681/ASN.2013080860
- Wändell P, Feldreich T, Larsson A, et al. The association between TNF-receptors (TNFR1 and TNFR2) and mortality as well as kidney function decline in patients with chronic kidney disease. Ups J Med Sci. 2024;129:e10726. doi:10.48101/ujms.v129.10726
- Chang LH, Chang TT, Chu CH, Huang CC, Lin LY. Soluble tumor necrosis factor receptor type 1 is an alternative marker of urinary albumin-creatinine ratio and estimated glomerular filtration rate for predicting the decline of renal function in subjects with type 2 diabetes mellitus. Clin Chim Acta. 2024;558:117880. doi:10.1016/j.cca.2024.117880
- Niewczas MA, Pavkov ME, Skupien J, et al. A signature of circulating inflammatory proteins and development of end-stage renal disease in diabetes. Nat Med. 2019;25(5):805-813. doi:10.1038/s41591-019-0415-5
- Liu Y, Xu K, Xiang Y, et al. Role of MCP-1 as an inflammatory biomarker in nephropathy. Front Immunol. 2024;14:1303076. doi:10.3389/fimmu.2023.1303076
- Anders HJ. Of inflammasomes and alarmins: IL-1β and IL-1α in kidney disease. J Am Soc Nephrol. 2016;27(9):2564-2575. doi:10.1681/ASN.2016020177
- Pathak A, Agrawal A. Evolution of C-reactive protein. Front Immunol. 2019;10:943. doi:10.3389/fimmu.2019.00943
- Sproston NR, Ashworth JJ. Role of C-reactive protein at sites of inflammation and infection. Front Immunol. 2018;9:754. doi:10.3389/fimmu.2018.00754
- Zhou HH, Tang YL, Xu TH, Cheng B. C-reactive protein: structure, function, regulation, and role in clinical diseases. Front Immunol. 2024;15:1425168. doi:10.3389/fimmu.2024.1425168
- Wang N, Zhang C. Recent advances in the management of diabetic kidney disease: slowing progression. Int J Mol Sci. 2024;25(6):3086. doi:10.3390/ijms25063086
- Tesch GH. MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy. Am J Physiol Renal Physiol. 2008;294(4):F697-F701. doi:10.1152/ajprenal.00016.2008
- Yang K, Fang Y, He J, Li J. Adipokine networks in diabetic kidney disease: mechanistic insights and therapeutic implications. Lipids Health Dis. 2026;25(1):43. doi:10.1186/s12944-025-02851-9
- Waanders F, van Timmeren MM, Stegeman CA, Bakker SJ, van Goor H. Kidney injury molecule-1 in renal disease. J Pathol. 2010;220(1):7-16. doi:10.1002/path.2642
- Mori Y, Ajay AK, Chang JH, et al. KIM-1 mediates fatty acid uptake by renal tubular cells to promote progressive diabetic kidney disease. Cell Metab. 2021;33(5):1042-1061.e7. doi:10.1016/j.cmet.2021.04.004
- Yin JM, Li Y, Xue JT, Zong GW, Fang ZZ, Zou L. Explainable machine learning-based prediction model for diabetic nephropathy. J Diabetes Res. 2024;2024:8857453. doi:10.1155/2024/8857453
- Limonte CP, Prince DK, Hoofnagle AN, et al. Kidney tubular biomarkers in type 1 diabetes: longitudinal analysis of 2 cohorts. Kidney Int Rep. 2025;10(7):2311-2322. doi:10.1016/j.ekir.2025.04.057
- Żyłka A, Dumnicka P, Kuśnierz-Cabala B, et al. Markers of glomerular and tubular damage in the early stage of kidney disease in type 2 diabetic patients. Mediators Inflamm. 2018;2018:7659243. doi:10.1155/2018/7659243
- van Timmeren MM, van den Heuvel MC, Bailly V, Bakker SJ, van Goor H, Stegeman CA. Tubular kidney injury molecule-1 (KIM-1) in human renal disease. J Pathol. 2007;212(2):209-217. doi:10.1002/path.2175
- Bieniaś B, Zajączkowska M, Borzęcka H, Sikora P, Wieczorkiewicz-Płaza A, Wilczyńska B. Early markers of tubulointerstitial fibrosis in children with idiopathic nephrotic syndrome: preliminary report. Medicine (Baltimore). 2015;94(42):e1746. doi:10.1097/MD.0000000000001746
- Zhang WR, Parikh CR. Biomarkers of acute and chronic kidney disease. Annu Rev Physiol. 2019;81:309-333. doi:10.1146/annurev-physiol-020518-114605
- Jaberi SA, Cohen A, D’Souza C, et al. Lipocalin-2: structure, function, distribution and role in metabolic disorders. Biomed Pharmacother. 2021;142:112002. doi:10.1016/j.biopha.2021.112002
- Romejko K, Markowska M, Niemczyk S. The review of current knowledge on neutrophil gelatinase-associated lipocalin (NGAL). Int J Mol Sci. 2023;24(13):10470. doi:10.3390/ijms241310470
- Devarajan P. Neutrophil gelatinase-associated lipocalin (NGAL): a new marker of kidney disease. Scand J Clin Lab Invest Suppl. 2008;241:89-94. doi:10.1080/00365510802150158
- Kamijo-Ikemori A, Sugaya T, Ichikawa D, et al. Urinary liver type fatty acid binding protein in diabetic nephropathy. Clin Chim Acta. 2013;424:104-108. doi:10.1016/j.cca.2013.05.020
- Schrezenmeier EV, Barasch J, Budde K, Westhoff T, Schmidt-Ott KM. Biomarkers in acute kidney injury – pathophysiological basis and clinical performance. Acta Physiol (Oxf). 2017;219(3):556-574. doi:10.1111/apha.12764
- Omozee EB, Okaka EI, Edo AE, Obika LF. Urinary N-acetyl-beta-d-glucosaminidase levels in diabetic adults. J Lab Physicians. 2019;11(1):1-4. doi:10.4103/JLP.JLP_164_17
- Yang H, Chen Y, He J, Li Y, Feng Y. Advances in the diagnosis of early biomarkers for acute kidney injury: a literature review. BMC Nephrol. 2025;26(1):115. doi:10.1186/s12882-025-04040-3
- Adiyanti SS, Loho T. Acute kidney injury (AKI) biomarker. Acta Med Indones. 2012;44(3):246-255.
- D’Amico G, Bazzi C. Pathophysiology of proteinuria. Kidney Int. 2003;63(3):809-825. doi:10.1046/j.1523-1755.2003.00840.x
- Masakane I, Sakurai K. Current approaches to middle molecule removal: room for innovation. Nephrol Dial Transplant. 2018;33(Suppl 3):iii12-iii21. doi:10.1093/ndt/gfy224
- Wang L, Wang HL, Liu TT, Lan HY. TGF-beta as a master regulator of diabetic nephropathy. Int J Mol Sci. 2021;22(15):7881. doi:10.3390/ijms22157881
- Hong Q, Kim H, Cai GY, Chen XM, He JC, Lee K. Modulation of TGF-β signaling: new approaches toward kidney disease and fibrosis therapy. Int J Biol Sci. 2025;21(4):1649-1665. doi:10.7150/ijbs.101548
- Gewin LS. TGF-β and diabetic nephropathy: lessons learned over the past 20 years. Am J Med Sci. 2020;359(2):70-72. doi:10.1016/j.amjms.2019.11.010
- Sthaneshwar P, Chan SP. Urinary type IV collagen levels in diabetes mellitus. Malays J Pathol. 2010;32(1):43-47.
- Iijima T, Suzuki S, Sekizuka K, et al. Follow-up study on urinary type IV collagen in patients with early stage diabetic nephropathy. J Clin Lab Anal. 1998;12(6):378-382. doi:10.1002/(SICI)1098-2825(1998)12:6<378::AID-JCLA8>3.0.CO;2-J
- Wang S, Li B, Li C, Cui W, Miao L. Potential renoprotective agents through inhibiting CTGF/CCN2 in diabetic nephropathy. J Diabetes Res. 2015;2015:962383. doi:10.1155/2015/962383
- Riser BL, Cortes P, DeNichilo M, et al. Urinary CCN2 (CTGF) as a possible predictor of diabetic nephropathy: preliminary report. Kidney Int. 2003;64(2):451-458. doi:10.1046/j.1523-1755.2003.00130.x
- Fukuda A, Sato Y, Shibata H, Fujimoto S, Wiggins RC. Urinary podocyte markers of disease activity, therapeutic efficacy, and long-term outcomes in acute and chronic kidney diseases. Clin Exp Nephrol. 2024;28(6):496-504. doi:10.1007/s10157-024-02465-y
- Kostovska I, Tosheska-Trajkovska K, Topuzovska S, et al. Urinary nephrin is earlier, more sensitive and specific marker of diabetic nephropathy than microalbuminuria. J Med Biochem. 2020;39(1):83-90. doi:10.2478/jomb-2019-0026
- Wang R, Yao C, Liu F. Association between renal podocalyxin expression and renal dysfunction in patients with diabetic nephropathy: a single-center, retrospective case-control study. Biomed Res Int. 2020;2020:7350781. doi:10.1155/2020/7350781
- He FF, Li HQ, Huang QX, et al. Tumor necrosis factor-alpha and 8-hydroxy-2′-deoxyguanosine are associated with elevated urinary angiopoietin-2 level in type 2 diabetic patients with albuminuria. Kidney Blood Press Res. 2015;40(4):355-365. doi:10.1159/000368510
- Spoto B, Politi C, Pizzini P, et al. 8-hydroxy-2′-deoxyguanosine, a biomarker of oxidative DNA injury, in diabetic kidney disease. Nutr Metab Cardiovasc Dis. 2025;35(2):103722. doi:10.1016/j.numecd.2024.08.015
- Il’yasova D, Scarbrough P, Spasojevic I. Urinary biomarkers of oxidative status. Clin Chim Acta. 2012;413(19-20):1446-1453. doi:10.1016/j.cca.2012.06.012
- Montero A, Munger KA, Khan RZ, et al. F2-isoprostanes mediate high glucose-induced TGF-β synthesis and glomerular proteinuria in experimental type I diabetes. Kidney Int. 2000;58(5):1963-1972. doi:10.1111/j.1523-1755.2000.00368.x
- Mahashabde ML, Chauhan RS, Paidi SKR, Sriram PJ. Study of cystatin C and renal resistive index in type 2 diabetes mellitus patients to detect early diabetic kidney disease. Ann Afr Med. 2026;25(2):424-430. doi:10.4103/aam.aam_124_25
- Shimizu A, Horikoshi S, Rinnno H, Kobata M, Saito K, Tomino Y. Serum cystatin C may predict the early prognostic stages of patients with type 2 diabetic nephropathy. J Clin Lab Anal. 2003;17(5):164-167. doi:10.1002/jcla.10087
- Yu C. Serum homocysteine (Hcy), cystatin C (Cys-C), and urine microalbumin (mAlb) are critical for early diagnosis of diabetic nephropathy. Am J Transl Res. 2025;17(9):7408-7425. doi:10.62347/DMQO5042
- Inker LA, Eneanya ND, Coresh J, et al. New creatinine- and cystatin C-based equations to estimate GFR without race. N Engl J Med. 2021;385(19):1737-1749. doi:10.1056/NEJMoa2102953
- Fan Y, Fei Y, Zheng L, et al. Expression of endothelial cell injury marker CD146 correlates with disease severity and predicts the renal outcomes in patients with diabetic nephropathy. Cell Physiol Biochem. 2018;48(1):63-74. doi:10.1159/000491663
- Schrijvers BF, Flyvbjerg A, De Vriese AS. The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int. 2004;65(6):2003-2017. doi:10.1111/j.1523-1755.2004.00621.x
- Lin S, Teng J, Li J, Sun F, Yuan D, Chang J. Association of chemerin and vascular endothelial growth factor (VEGF) with diabetic nephropathy. Med Sci Monit. 2016;22:3209-3214. doi:10.12659/MSM.896781
- Ho PTB, Clark IM, Le LTT. MicroRNA-based diagnosis and therapy. Int J Mol Sci. 2022;23(13):7167. doi:10.3390/ijms23137167
- Jiang L, Li L, Zhang K, et al. A systematic review and meta-analysis of microRNAs in the diagnosis of early diabetic kidney disease. Front Endocrinol (Lausanne). 2025;16:1432652. doi:10.3389/fendo.2025.1432652
- Liu S, Wu W, Liao J, et al. MicroRNA-21: a critical pathogenic factor of diabetic nephropathy. Front Endocrinol (Lausanne). 2022;13:895010. doi:10.3389/fendo.2022.895010
- Wan X, Liao J, Lai H, Zhang S, Cui J, Chen C. Roles of microRNA-192 in diabetic nephropathy: the clinical applications and mechanisms of action. Front Endocrinol (Lausanne). 2023;14:1179161. doi:10.3389/fendo.2023.1179161
- Szostak J, Gorący A, Durys D, Dec P, Modrzejewski A, Pawlik A. The role of microRNA in the pathogenesis of diabetic nephropathy. Int J Mol Sci. 2023;24(7):6214. doi:10.3390/ijms24076214
- Tonolo G, Cherchi S. Tubulointerstitial disease in diabetic nephropathy. Int J Nephrol Renovasc Dis. 2014;7:107-115. doi:10.2147/IJNRD.S37883
- Zhou LT, Lv LL, Qiu S, et al. Bioinformatics-based discovery of the urinary BBOX1 mRNA as a potential biomarker of diabetic kidney disease. J Transl Med. 2019;17(1):59. doi:10.1186/s12967-019-1818-2
- Zou LX, Hou ZL, Qian CH, Wang X, Sun L. Performance of novel biomarkers for prediction of diabetic kidney disease in patients with diabetes mellitus. Ann Med. 2025;57(1):2562996. doi:10.1080/07853890.2025.2562996
- Colhoun HM, Marcovecchio ML. Biomarkers of diabetic kidney disease. Diabetologia. 2018;61(5):996-1011. doi:10.1007/s00125-018-4567-5
- Gluhovschi C, Gluhovschi G, Petrica L, et al. Urinary biomarkers in the assessment of early diabetic nephropathy. J Diabetes Res. 2016;2016:4626125. doi:10.1155/2016/4626125
- Lee SY, Choi ME. Urinary biomarkers for early diabetic nephropathy: beyond albuminuria. Pediatr Nephrol. 2015;30(7):1063-1075. doi:10.1007/s00467-014-2888-2
- Betz BB, Jenks SJ, Cronshaw AD, et al. Urinary peptidomics in a rodent model of diabetic nephropathy highlights epidermal growth factor as a biomarker for renal deterioration in patients with type 2 diabetes. Kidney Int. 2016;89(5):1125-1135. doi:10.1016/j.kint.2016.01.015
- Dubin RF, Rhee EP. Proteomics and metabolomics in kidney disease, including insights into etiology, treatment, and prevention. Clin J Am Soc Nephrol. 2020;15(3):404-411. doi:10.2215/CJN.07420619
- Božičević S, Vučić Lovrenčić M, Smirčić Duvnjak L. Diagnostic challenges of diabetic kidney disease. Biochem Med (Zagreb). 2023;33(3):030501. doi:10.11613/BM.2023.030501
- Mu H, Zhang Q, Huang W, et al. The serum uric acid to creatinine ratio as a diagnostic biomarker for normoalbuminuric diabetic kidney disease. Front Med (Lausanne). 2025;12:1584049. doi:10.3389/fmed.2025.1584049
Article information
Authors
- Anupriya VeluDepartment of Biochemistry, Faculty of Medicine, Shri Gorakshnath Medical College, Hospital and Research Center, Mahayogi Gorakhnath University, Gorakhpur, India
- Palani Selvam MohanrajDepartment of Biochemistry, All India Institute of Medical Sciences, Gorakhpur, IndiaCorresponding author · [email protected]
- Suresh K SrinivasanDirector of Pain Medicine, Trinity Health System, Steubenville, OH 43952, United States
- Anupama OjhaDepartment of Biochemistry, Faculty of Medicine, Shri Gorakshnath Medical College, Hospital and Research Center, Mahayogi Gorakhnath University, Gorakhpur, India
- Vinoth RajendranDepartment of Community Medicine and Family Medicine, All India Institute of Medical Sciences, Gorakhpur, India
- Srinivas NagaramDepartment of Biochemistry, All India Institute of Medical Sciences, Gorakhpur, India
How to cite
Velu, A., Mohanraj, P. S., et al., 2026. Beyond Microalbuminuria: A Narrative Review of Inflammatory, Tubular, Glomerular, and Oxidative Stress Biomarkers for Early Diabetic Kidney Disease. Medical Research Archives, [online] 14(10). https://doi.org/10.18103/mra.2026.0630
Record
- Journal
- Medical Research Archives
- Issue
- Vol 14 No 10 (2026)
- Section
- Review Articles
- Published
- 31 October 2026
- ISSN
- 2375-1924
- Downloads
- 75
Copyright and licence
Published by the European Society of Medicine under a Creative Commons Attribution 4.0 International licence (CC BY 4.0), which permits unrestricted use, distribution and reproduction in any medium, provided the original authors and source are credited.